On March 26, Moscow hosted a Russian Association of Pharmaceutical Marketing (RAPM) conference, “New Threats and Opportunities of Russian Pharmaceutical Market in 2015”. Within the agenda of the conference, RNC Pharma published a forecast of the Russian pharmaceutical market after the monetary crisis of 2014-2015.
Any crisis is accompanied by a surge of the regulatory activity of the state, with the consequences for the future development of the market being often as serious as those of the crisis. That was the case in 2009-2010, when the market was getting used to functioning under the current price regulation, and that will be the case in 2015-2016, but there are many more regulation initiatives now.
Apparently, the most crucial for the market will be the change of the process of state import of pharmaceutical drugs, in particular the limitation of the access to bids for those foreign pharmaceutical drugs that have 2 or more alternatives of Russian, Belorussian or Kazakhstan origin.
The legalization of parallel import of pharmaceutical drugs to Russia, long-term contracts with suppliers, the development of public pharmacies as well as a possibility of compulsory licensing of pharmaceutical drugs may also have serious consequences for the market.
Please download the Powerpoint presentation here.